[go: up one dir, main page]

AR057239A1 - Inmunoglobulinas - Google Patents

Inmunoglobulinas

Info

Publication number
AR057239A1
AR057239A1 ARP060105524A ARP060105524A AR057239A1 AR 057239 A1 AR057239 A1 AR 057239A1 AR P060105524 A ARP060105524 A AR P060105524A AR P060105524 A ARP060105524 A AR P060105524A AR 057239 A1 AR057239 A1 AR 057239A1
Authority
AR
Argentina
Prior art keywords
immunoglobulins
antibodies
prophylaxis
disorders
refers
Prior art date
Application number
ARP060105524A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35736284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR057239(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR057239A1 publication Critical patent/AR057239A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente se refiere a anticuerpos de NOGO, a formulaciones farmacéuticas que los contienen y al uso de tales anticuerpos en el tratamiento y/o profilaxis de enfermedades/trastornos neurologicos.
ARP060105524A 2005-12-16 2006-12-14 Inmunoglobulinas AR057239A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0525662.3A GB0525662D0 (en) 2005-12-16 2005-12-16 Immunoglobulins

Publications (1)

Publication Number Publication Date
AR057239A1 true AR057239A1 (es) 2007-11-21

Family

ID=35736284

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105524A AR057239A1 (es) 2005-12-16 2006-12-14 Inmunoglobulinas

Country Status (30)

Country Link
US (2) US8362208B2 (es)
EP (2) EP2228391A3 (es)
JP (1) JP5015949B2 (es)
KR (1) KR101355118B1 (es)
CN (1) CN101374863B (es)
AR (1) AR057239A1 (es)
AU (1) AU2006325228B2 (es)
BR (1) BRPI0619855A2 (es)
CA (1) CA2633501C (es)
CR (1) CR10099A (es)
CY (1) CY1113094T1 (es)
DK (1) DK1960429T3 (es)
EA (1) EA015536B1 (es)
ES (1) ES2389380T3 (es)
GB (1) GB0525662D0 (es)
HR (1) HRP20120684T1 (es)
IL (1) IL192086A0 (es)
JO (1) JO2795B1 (es)
MA (1) MA30041B1 (es)
MY (1) MY149492A (es)
NO (1) NO20082699L (es)
NZ (1) NZ569143A (es)
PE (1) PE20071099A1 (es)
PL (1) PL1960429T3 (es)
PT (1) PT1960429E (es)
SI (1) SI1960429T1 (es)
TW (1) TWI378940B (es)
UA (1) UA96279C2 (es)
WO (1) WO2007068750A2 (es)
ZA (2) ZA200805111B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5698534B2 (ja) * 2007-11-02 2015-04-08 ノバルティス アーゲー 改良されたｎｏｇｏ−ａ結合分子およびその医薬的使用
US8669349B2 (en) 2008-04-02 2014-03-11 Macrogenics, Inc. BCR-complex-specific antibodies and methods of using same
WO2009135853A2 (en) 2008-05-06 2009-11-12 Glaxo Group Limited Encapsulation of biologically active agents
JP2011527317A (ja) * 2008-07-11 2011-10-27 グラクソ グループ リミテッド Ｎｏｇｏ−ａアンタゴニストによる筋萎縮性側索硬化症の治療
US8828390B2 (en) 2010-07-09 2014-09-09 Universitat Zurich Uses of NOGO-A inhibitors and related methods
WO2014006105A1 (en) 2012-07-05 2014-01-09 Glaxo Group Limited Optimum dose regime of an anti-nogo-a antibody in the treatment of amyotrophic lateral sclerosis
US20180362660A1 (en) * 2016-05-09 2018-12-20 Schickwann Tsai Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes
US11013815B2 (en) 2017-06-14 2021-05-25 Monojul, Llc High-affinity anti-human folate receptor beta antibodies and methods of use
AU2020293734A1 (en) * 2019-06-13 2022-01-27 Prestige Biopharma Pte. Ltd. Novel antibodies specific for CTHRC1 and use thereof
JP7788996B2 (ja) 2019-10-24 2025-12-19 ノヴァゴー セラピューティクス アーゲー 新規抗Ｎｏｇｏ－Ａ抗体
GB202012331D0 (en) 2020-08-07 2020-09-23 Petmedix Ltd Therapeutic antibodies
MX2023015152A (es) 2021-06-17 2024-05-31 Petmedix Ltd Anticuerpos anti-cd20 canino.
KR20240099321A (ko) 2021-10-21 2024-06-28 펫메딕스 리미티드 P75ntr의 세포외 도메인을 포함하는 단백질
CN116251181B (zh) * 2021-12-02 2023-09-22 北京东方百泰生物科技股份有限公司 一种抗tslp单克隆抗体的注射制剂
EP4476256A1 (en) 2022-02-09 2024-12-18 Petmedix Ltd. Therapeutic antibodies
CN119768424A (zh) * 2022-08-22 2025-04-04 舒泰神（北京）生物制药股份有限公司 特异性识别Nogo-A的抗体及其应用
GB202217993D0 (en) 2022-11-30 2023-01-11 Petmedix Ltd Therapeutic antibodies
CN120712277A (zh) 2023-02-09 2025-09-26 佩特迈迪有限公司 包含p75神经营养因子受体(p75ntr)胞外结构域变体的治疗分子

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5250414A (en) 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1994004690A1 (en) 1992-08-17 1994-03-03 Genentech, Inc. Bispecific immunoadhesins
GB9403250D0 (en) 1994-02-21 1994-04-13 Univ Mcgill Therapeutic use of myelin-associated glycoprotein (mag)
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
DE69531458T2 (de) 1994-05-27 2004-08-05 Glaxosmithkline S.P.A. Chinolinderivate als tachykinin nk3 rezeptor antagonisten
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
JP4841017B2 (ja) 1995-06-27 2011-12-21 リサーチ ファウンデーション オブ シーユーエヌワイ， ハンター カレッジ ミエリン会合糖タンパク質（ｍａｇ）およびそのインヒビターを用いた組成物および方法
US6420338B1 (en) * 1997-06-13 2002-07-16 New York University Medical Center Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
ATE483021T1 (de) 1998-07-22 2010-10-15 Smithkline Beecham Ltd Protein, das mit einem neuroendokrinspezifischen protein änhelt, und dafür kodierende cdns
CZ304224B6 (cs) 1998-11-06 2014-01-15 Schwab Monoklonální protilátka
FR2792199B3 (fr) 1999-04-13 2001-05-18 Sanofi Sa Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur
US6881557B2 (en) 2001-07-12 2005-04-19 Arrowsmith Technologies Llp Super humanized antibodies
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
GB0318727D0 (en) 2003-08-08 2003-09-10 Smithkline Beecham Corp Novel compounds
DE10338136A1 (de) 2003-08-15 2005-03-24 European Molecular Biology Laboratory Zentrifuge und ein Träger zur Verwendung in einer Zentrifuge
GB0321997D0 (en) 2003-09-19 2003-10-22 Novartis Ag Organic compound
AU2004303585B2 (en) * 2003-12-22 2010-12-23 Glaxo Group Limited NOGO-a neutralising immunoglobulins for treatment of neurological diseases
WO2005069970A2 (en) * 2004-01-20 2005-08-04 Kalobios, Inc. Antibody specificity transfer using minimal essential binding determinants
WO2005097184A2 (en) * 2004-03-26 2005-10-20 Human Genome Sciences, Inc. Antibodies against nogo receptor

Also Published As

Publication number Publication date
NO20082699L (no) 2008-09-08
MY149492A (en) 2013-09-13
CR10099A (es) 2008-09-22
IL192086A0 (en) 2008-12-29
CA2633501A1 (en) 2007-06-21
ZA200906162B (en) 2010-05-26
GB0525662D0 (en) 2006-01-25
SI1960429T1 (sl) 2012-09-28
WO2007068750A3 (en) 2007-11-29
DK1960429T3 (da) 2012-09-24
NZ569143A (en) 2011-08-26
CA2633501C (en) 2015-03-31
EP2228391A2 (en) 2010-09-15
CY1113094T1 (el) 2016-04-13
PT1960429E (pt) 2012-09-25
AU2006325228A1 (en) 2007-06-21
EP2228391A3 (en) 2010-12-29
TWI378940B (en) 2012-12-11
ZA200805111B (en) 2009-12-30
PL1960429T3 (pl) 2012-11-30
AU2006325228B2 (en) 2011-12-15
HK1119720A1 (en) 2009-03-13
ES2389380T3 (es) 2012-10-25
JP5015949B2 (ja) 2012-09-05
UA96279C2 (ru) 2011-10-25
US20130287781A1 (en) 2013-10-31
PE20071099A1 (es) 2007-11-22
KR20080080644A (ko) 2008-09-04
US20100221260A1 (en) 2010-09-02
KR101355118B1 (ko) 2014-02-06
TW200801038A (en) 2008-01-01
MA30041B1 (fr) 2008-12-01
JO2795B1 (en) 2014-03-15
EP1960429A2 (en) 2008-08-27
WO2007068750A2 (en) 2007-06-21
HRP20120684T1 (hr) 2012-09-30
US8362208B2 (en) 2013-01-29
BRPI0619855A2 (pt) 2011-10-25
EP1960429B1 (en) 2012-06-27
EA200801343A1 (ru) 2008-12-30
JP2009519025A (ja) 2009-05-14
CN101374863B (zh) 2013-05-29
EA015536B1 (ru) 2011-08-30
CN101374863A (zh) 2009-02-25

Similar Documents

Publication Publication Date Title
AR048912A1 (es) Inmunoglobulinas anti-nogo
CR10099A (es) Inmunoglobulinas dirigidas contra nogo
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
HN2004000319A (es) "{ 1,8}naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia"
UY33616A (es) Compuestos con estructura de imidazotriazinona
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
HN2002000275A (es) Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados
UY28752A1 (es) Agentes terapeuticos
CL2012003293A1 (es) Compuestos derivados de aminopirimidina, como moduladores de la proteina quinasa rica en repeticiones leucina 2 (lrrk2); composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de parkinson.
ECSP088283A (es) Compuestos de piridina 5- (fenilisoxazoliletoxi) -triazol- 3-ilo substituidos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
CR8858A (es) Derivados de sulfamato y sulfamida para el tratamiento de epilepsia y trastornos relacionados
ECSP088804A (es) Antagonistas de los piridil amida de los canales de calcio de tipo t
GT200900121A (es) Moleculas de enlace de lingo y uso farmaceutico
ECSP067043A (es) Derivados de pirrolotriazina útiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogénesis
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
ECSP099490A (es) Métodos de fabricación y uso de compuestos y composiciones
ECSP034810A (es) Derivados heterociclilalcoxi-, -alquiltio- y - alquilaminobenzazol tales como ligandos 5-hidroxitriptamina-6
CL2024000459A1 (es) Tubulisinas y conjugados de proteína-tubulisina.
ECSP11010956A (es) Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos
CL2008001820A1 (es) Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer.
GT200600135A (es) Forma cristalina ortorrombica del maleato de asenapina y su uso en el tratamiento de trastornos mentales
CR9623A (es) Anticuerpos humanizados especificos para nogo-a y sus usos farmaceuticos
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
GT200600161A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos
CL2009000599A1 (es) Compuestos derivados de 4,5-dihidro-1h-pirazol(4,3-g)benzotiazol sustituidos; composicion farmaceutica; utiles para el tratamiento y prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes, entre otras.

Legal Events

Date Code Title Description
FG Grant, registration
FG Grant, registration